Edmunds LH Jr, Clark RE, Cohn LH, et al. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison Committee for standardizing definitions of prosthetic heart valve morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg. 1996;112:708–11.

Article  PubMed  Google Scholar 

Gürsoy MO, Kalçık M, Yesin M, et al. A global perspective on mechanical prosthetic heart valve thrombosis: diagnostic and therapeutic challenges. Anatol J Cardiol. 2016;16:980–9.

PubMed  PubMed Central  Google Scholar 

Kalcik M, Gursoy MO, Karakoyun S, Yesin M, et al. Potential inherited causes of recurrent prosthetic mitral valve thrombosis in a pregnant patient suffering from recurrent miscarriage. Korean Circ J. 2014;44:268–70.

Article  PubMed  PubMed Central  Google Scholar 

Aykan AC, Gökdeniz T, Gündüz S, et al. Value of serum fibrinogen levels in the assessment of mechanical prosthetic valve thrombosis. J Heart Valve Dis. 2014;23:222–7.

PubMed  Google Scholar 

Aykan AÇ, Gökdeniz T, Kalçık M, et al. Role of anticardiolipin antibodies in the pathogenesis of prosthetic valve thrombosis: an observational study. Herz. 2015;40:528–33.

Article  CAS  PubMed  Google Scholar 

Özkan M, Kalçık M, Gürsoy MO, et al. Assessment of anti-tissue type plasminogen activator antibodies in patients with prosthetic heart valve thrombosis: the ATA trial. J Cardiovasc Pharmacol Ther. 2016;21:372–80.

Article  PubMed  Google Scholar 

Astarcıoğlu MA, Kalçık M, Yesin M, et al. AB0 blood types: impact on development of prosthetic mechanical valve thrombosis. Anatol J Cardiol. 2016;16:820–3.

PubMed  PubMed Central  Google Scholar 

Bayam E, Kalçık M, Gürbüz AS, et al. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. Thromb Res. 2018;171:103–10.

Article  CAS  PubMed  Google Scholar 

Kaya H, Ozkan M, Yildiz M. Relationship between endothelial dysfunction and prosthetic heart valve thrombosis: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2013;17(12):1594–8.

CAS  PubMed  Google Scholar 

Etingin OR, Hajjar DP, Hajjar KA, et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991;266:2459–65.

Article  CAS  PubMed  Google Scholar 

Buechler C, Ullrich H, Ritter M, et al. Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 2001;97:981–6.

Article  CAS  PubMed  Google Scholar 

Onat A, Hergenç G, Ozhan H, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis. 2008;19:125–31.

Article  PubMed  Google Scholar 

Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23.

Article  Google Scholar 

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low- density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.

Article  CAS  PubMed  Google Scholar 

Ozkan M, Gündüz S, Güner A, et al. Thrombolysis or surgery in patients with obstructive mechanical valve thrombosis: the multicenter HATTUSHA study. J Am Coll Cardiol. 2022;79(10):977–89.

PubMed  Google Scholar 

Black IW, Hopkins AP, Lee LCL, Walsh WF. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J Am Coll Cardiol. 1991;18(2):398–404.

Article  CAS  PubMed  Google Scholar 

Zoghbi WA, Jone PN, Chamsi-Pasha MA, et al. Guidelines for the evaluation of prosthetic valve function with cardiovascular imaging: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2024;37(1):2–63. https://doi.org/10.1016/j.echo.2023.10.004.

Article  PubMed  Google Scholar 

Ozkan M, Gunduz S, Biteker M, et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging. 2013;6:206–16.

Article  PubMed  Google Scholar 

Ozkan M, Cakal B, Karakoyun S, et al. Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue- type plasminogen activator. Circulation. 2013;128:532–40.

Article  PubMed  Google Scholar 

Gündüz S, Özkan M, Kalçik M, et al. Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve dysfunction: thrombus or pannus. Circ Cardiovasc Imaging. 2015;8:e003246.

Article  PubMed  Google Scholar 

Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–82.

Article  CAS  PubMed  Google Scholar 

Scanu AM1, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest. 1990;85:1709–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rouy D, Grailhe P, Nigon F, et al. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb. 1991;11:629–38.

Article  CAS  PubMed  Google Scholar 

Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem. 2003;278:23260–9.

Article  CAS  PubMed  Google Scholar 

Özkan M, Gündüz S, Gürsoy OM, et al. A novel strategy in the management of PROsthetic Mechanical valve Thrombosis and the prEdictors of outcomE: the Ultra- slow PROMETEE trial. Am Heart J. 2015;170:409–18.

Article  PubMed  Google Scholar 

Levin EG, Miles LA, Fless GM, et al. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb. 1994;14(3):438–42.

Article  CAS  PubMed  Google Scholar 

Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998;18:1393–9.

Article  CAS  PubMed  Google Scholar 

Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood. 2001;98:2980–7.

Article  CAS  PubMed  Google Scholar 

Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease:the PRIME study. Atherosclerosis. 2002;163:377–84.

Article  CAS  PubMed  Google Scholar 

Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003;14:361–6.

Article  CAS  PubMed  Google Scholar 

Seman LJ, DeLuca C, Jenner JL, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem. 1999;45:1039–46.

Article  CAS  PubMed  Google Scholar 

Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082–5.

Article  CAS  PubMed  Google Scholar 

Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arterioscler. 1989;9:579–92.

Article  CAS